Amyloid plaques

Amyloid plaques are a defining feature of Alzheimer's disease, consisting of dense, insoluble deposits of a protein fragment called amyloid-beta (Aβ). These plaques form in the extracellular spaces of the brain, particularly in regions crucial for memory and cognition, such as the hippocampus and cerebral cortex. The Aβ protein itself is derived from a larger membrane protein known as the amyloid precursor protein (APP), which is believed to play a role in synaptic formation and repair. In a pathological process, APP is cleaved by two enzymes, beta-secretase and gamma-secretase, releasing Aβ fragments of varying lengths.

The most common forms are Aβ40 and Aβ42. While Aβ40 is more abundant, the Aβ42 fragment is considered more neurotoxic because its chemical properties make it "stickier" and more prone to misfolding and aggregation. These individual Aβ42 monomers clump together to form small, soluble clusters called oligomers, which then assemble into larger protofibrils and fibrils. Over time, these fibrils deposit and mature into the large, insoluble amyloid plaques that can be observed under a microscope in the brain tissue of individuals with Alzheimer's disease.

The discovery of amyloid plaques led to the formulation of the "amyloid cascade hypothesis" in the early 1990s. This influential theory proposes that the accumulation of Aβ is the initiating event in Alzheimer's pathology, triggering a downstream cascade that includes the hyperphosphorylation of tau protein (leading to neurofibrillary tangles inside neurons), neuroinflammation, synaptic loss, and widespread neuronal death. For decades, this hypothesis has been the dominant framework for Alzheimer's research and drug development.

However, the precise role of amyloid plaques in cognitive decline is complex and still debated. The correlation between plaque density and the severity of dementia is not always strong; some cognitively normal elderly individuals are found to have significant plaque burdens at autopsy. This has led to a refinement of the hypothesis, with many researchers now believing that the smaller, soluble Aβ oligomers, rather than the large, inert plaques, are the primary toxic species that disrupt synaptic function and drive neurodegeneration. From this perspective, the plaques may represent a biological attempt to sequester these more dangerous oligomers into a less harmful, consolidated form.

For patients and clinicians, amyloid plaques serve as a critical biomarker for the diagnosis of Alzheimer's disease. Their presence can be detected in living individuals through advanced neuroimaging techniques, such as positron emission tomography (PET) scans, or by measuring Aβ levels in cerebrospinal fluid. This allows for earlier and more accurate diagnosis, distinguishing Alzheimer's from other forms of dementia.

Furthermore, amyloid plaques are a major target for therapeutic intervention. The development of monoclonal antibody drugs, such as lecanemab and donanemab, represents a significant milestone. These therapies are designed to bind to and clear amyloid deposits from the brain. Clinical trials have shown that reducing the plaque burden can modestly slow the rate of cognitive decline in patients with early-stage Alzheimer's disease. While not a cure, these treatments provide the first proof-of-concept that targeting the underlying pathology of Alzheimer's can alter its course, validating the importance of amyloid plaques in the disease process and offering hope for more effective future treatments.